Ambu A/S

Ambu A/S

AMBBY - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$3.49B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Ambu A/SAmbu A/S37.90.45%10%0.60.1

Earnings Call Q3 2026

August 26, 2026 - AI Summary

Strong momentum in single-use endoscopy (core of strategy) - Q3 delivered 10.3% organic growth; Endoscopy Solutions grew ~15% in the quarter (management cites 16% Endoscopy growth overall and Endoscopy is 64% of company revenue, continuing to rise). - Endoscopy is still the key growth engine driving the 15%+ organic growth expectation through the ZOOM AHEAD period. - Management emphasis: growth is largely driven by conversion from reusable to single-use rather than small market-share shifts.
Respiratory re-acceleration is a highlight (plus portfolio synergy) - Respiratory grew 17.1% in Q3 (driven by bronchoscopy portfolio: aScope 4/5), supported by SureSight videolaryngoscope (creates an adjacency + synergy with bronchoscope). - Rolling 12 months Respiratory growth ~11.5%, indicating sustained momentum beyond just a one-quarter spike. - Opportunity: management expects continued strong single-use conversion even though the market is more mature.
Urology / ENT / GI remains solid; A&PM turned positive but is still constrained - Urology/ENT/GI grew 15% in Q3; 16% growth overall of Endoscopy Solutions (rolling 12 months cited 16.9%). - Management attributed earlier volatility partly to deliberate U.S. commercial adjustments in April; momentum is continuing after those adjustments. - A&PM returned to positive growth in Q3 (+1.6% stated; rolling 12 months +1.3%), but is still expected to be low single-digit for the rest of the year due to annualization effects from volume losses on selected U.S. accounts (volume decline expected as a full-year effect). - Opportunity: new MRI/CT compatible electrodes (Neuroline Cup MRI/CT) should support longer-term growth recovery in A&PM.

Exclusive for Stockcircle Pro members

Sign upSign Up
$2.28

Current Fair Value

82.9% downside

Overvalued by 82.9% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$3.49 Billion
Enterprise Value$3.59 Billion
Annual dividend$0.06
Dividend yield0.45%
Earnings per Share$2.42
Beta1.45
Outstanding Shares262,765,957

Return

Return on Equity10.27%ROE
Return on Assets7.81%
Return on Invested Capital12.42%

Valuation & Multiples

P/E Ratio37.87P/E Ratio
PEG32.99PEG
Price to Sales0.55Price to Sales
Price to Book Ratio0.58Price to Book Ratio
Enterprise Value to Revenue0.55
Enterprise Value to EBIT4.18
Enterprise Value to Net Income5
Total Debt to Enterprise0.18
Debt to Equity0.1Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 5, 2026
EPS
$0.14
Reported
Revenue
$254.05 M
Est. $267.95 M

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Ambu A/S

5,384 employees
CEO: Britt Meelby Jensen

Ambu A/S engages in the development, production, and marketing of diagnostic and life-supporting devices for hospitals and rescue services. It operates through the following segments: Anaesthesia; Patient Monitoring & Diagnostics; and Vi...